Berlin, Germany - On April 14, Honghu Orthopedic Surgical Robot (Honghu) UX&UI System, developed by MicroPort NaviBot (Suzhou) Co., Ltd (MicroPort^® NaviBot^®), a subsidiary of Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort^® MedBot^®), won the "iF DESIGN AWARD 2023" from nearly 11,000 entries from 56 countries/regions for its smooth interactive experience, recognizable and easy-to-use interface design.

As the first and only Chinese-developed orthopedic surgery robot that has been approved by NMPA, FDA, and CE, Honghu Orthopedic Surgical Robot has always been developed with the goal of "more personalized, safe and precise, and minimally invasive" orthopedic surgery and "more efficient" operator experience, and has continuously improved its performance and UI&UX "triple black technology" since the R&D project started in 2015. As the iF judges said, "Honghu Orthopedic Surgical Robot assists surgeons in orthopedic surgery by providing individualized planning for different surgical sites. The linear workflow user interface (UI) helps surgeons create accurate, visualized 3D surgery plans. The combined robotic arm and optical tracking system provides real-time dynamic skeletal rendering and feedback on the tool's working status, and evaluates surgical outcomes during the procedure using visual data and animations."

In addition, the core components of Honghu, from robotic arm to navigation system and control system, are all self-developed, which fills the gap in the field of joint replacement surgery robot in China. Relying on the strong R&D strength of MicroPort^®, Honghu Orthopedic Surgical Robot has made breakthroughs in many underlying core technologies, making it a truly Chinese-developed product.

The use experience of Honghu is highly praised by domestic and foreign experts, which cannot be separated from the deep collaboration between domestic and foreign clinical experts and the Honghu team.

Huiwu Li, Director of the Department of Orthopedics at the Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine,

said:

The MedBot^® R&D team is very efficient and we are always in close communication from the R&D stage to production. During the product development process, the MedBot^®  R&D team immediately follows up and makes improvement upon the surgeons give their feedback after the validation experiments. The feedback efficiency is much higher than that of many R&D teams in foreign companies, which is not an easy job.

Doctor Joseph Kavolus, Lighthouse Surgical Hospital in New Hampshire, USA:

For the first Honghu-assisted total knee replacement procedure in the U.S., I was pleasantly surprised at the smooth flow and execution,  Good human-Robot interaction experience, and thrilled that the outcome was exceptional. I couldn't be happier to provide this to my patient.

Honghu was previously awarded the iF Product Design Award 2022 in 2022 for its strengths in five dimensions of design concept, product aesthetics, functional innovation, social impact, and uniqueness, and was honored with the Shanghai Silver Dove Award, the A' Design Award in Italy, and the Shanghai Design 100+ Award in 2021.

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot^® said, "We are honored to receive another prestigious international design award for the Honghu, which is a testament to the ability of MicroPort^® MedBot^® to uphold pioneering innovation and medical-industrial collaboration, translating its R&D and innovation capabilities into meeting a diverse range of clinical needs. The award will certainly motivate us to continuously pursue higher goals and dedicate ourselves to providing high-end, high-quality, integrated intelligent surgical total solutions that prolong and reshape lives."

1 The registered trademark of HongHu is named “Skywalker” in abroad, which is in the process of application in USA, completed registration in EU and other countries and regions.